BRIAN SANDOVAL
Governor

RICHARD WHITLEY, MS
Director

MARTA JENSEN
Administrator

DEPARTMENT OF HEALTH AND HUMAN SERVICES
DIVISION OF HEALTH CARE FINANCING AND POLICY
1100 East William Street, Suite 101
Carson City, Nevada 89701
Telephone (775) 684-3676 • Fax (775) 687-3893
http://dhcfp.nv.gov

NOTICE OF PUBLIC MEETING – DRUG USE REVIEW BOARD

AGENDA

Date of Posting: June 26, 2018

Date of Meeting: July 26, 2018 at 5:15 PM

Name of Organization: The State of Nevada, Department of Health and Human Services (DHHS), The Division of Health Care Financing and Policy (DHCFP), Drug Use Review Board (DUR)

Place of Meeting: Hyatt Place Reno-Tahoe Airport
1790 E. Plumb Lane
Reno, Nevada 89502
Phone: (775) 826-2500

Webinar Registration: https://optum.webex.com/optum/onstage/g.php?MTID=e489029e0f4a10412c98900b80fa9e4d5

Or go to www.webex.com and enter the event number listed below.

Once you have registered for the meeting, you will receive an email message confirming your registration. This message will provide the information that you need to join the meeting.

Event Number: 642 793 124

Click "Join Now."

Follow the instructions that appear on your screen to join the audio portion of the meeting. Audio will be transmitted over the internet.

A password should not be necessary, but if asked use: bMwDCY@3

For Audio Only: Phone: (763) 957-6300
Event: 642 793 124

AGENDA

1. Call to order and roll call

2. Public comment on any matter on the agenda

3. Administrative

   a. For Possible Action: Review and Approve Meeting Minutes from April 26, 2018.

   b. Status Update by the DHCFP.

4. Clinical presentations

   a. For Possible Action: Discussion and possible adoption of updated prior authorization criteria and/or quantity limits for Hepatitis C Direct-Acting Antivirals.

      1. Public comment on proposed clinical prior authorization criteria.
      2. Presentation of utilization and clinical information.
      3. Discussion by Board and review of utilization data.
      4. Proposed adoption of updated prior authorization criteria.

   b. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for antibiotics.

      1. Public comment on proposed clinical prior authorization criteria.
      2. Presentation of utilization and clinical information.
      3. Discussion by Board and review of utilization data.
      4. Proposed adoption of updated prior authorization criteria.

   c. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for medications used in the treatment of hemophilia.

      1. Public comment on proposed clinical prior authorization criteria.
      2. Presentation of utilization and clinical information.
      3. Discussion by Board and review of utilization data.
      4. Proposed adoption of updated prior authorization criteria.

d. For Possible Action: Discussion and possible adoption of updated prior authorization criteria and/or quantity limits for medications used in the treatment of irritable-bowel syndrome.

1. Public comment on proposed clinical prior authorization criteria.
2. Presentation of utilization and clinical information.
3. Discussion by Board and review of utilization data.
4. Proposed adoption of updated prior authorization criteria.

e. For Possible Action: Discussion and possible adoption of prior authorization criteria for tezacaftor/ivacxaftor (Symdeko®).

1. Public comment on proposed clinical prior authorization criteria.
2. Presentation of utilization and clinical information.
3. Discussion by Board and review of utilization data.
4. Proposed adoption of updated prior authorization criteria.

f. For Possible Action: Discussion and possible adoption of updated prior authorization criteria for ivacaftor (Kalydeco®).

1. Public comment on proposed clinical prior authorization criteria.
2. Presentation of utilization and clinical information.
3. Discussion by Board and review of utilization data.
4. Proposed adoption of updated prior authorization criteria.

g. For Possible Action: Discussion and possible adoption of updated prior authorization criteria for topical immunomodulators.

1. Public comment on proposed clinical prior authorization criteria.
2. Presentation of utilization and clinical information.
3. Discussion by Board and review of utilization data.
4. Proposed adoption of updated prior authorization criteria.

h. For Possible Action: Discussion and possible adoption of prior authorization criteria for compounded medications.

1. Public comment on proposed clinical prior authorization criteria.
2. Presentation of utilization and clinical information.
3. Discussion by Board and review of utilization data.
4. Proposed adoption of updated prior authorization criteria.

i. For Possible Action: Discussion and possible adoption of updated prior authorization criteria for neuromuscular blocking muscle relaxants (botulinium toxin).

1. Public comment on proposed clinical prior authorization criteria.
2. Presentation of utilization and clinical information.

3. Discussion by Board and review of utilization data.
4. Proposed adoption of updated prior authorization criteria.

j. For Possible Action: Discussion and possible adoption of prior authorization criteria for opioid containing cough preparations.

1. Public comment on proposed clinical prior authorization criteria.
2. Presentation of utilization and clinical information.
3. Discussion by Board and review of utilization data.
4. Proposed adoption of updated prior authorization criteria.

5. Public comment on any DUR Board requested report

6. DUR Board requested reports

a. Pharmacy lock-in program.

1. Discussion by the Board and review of utilization data.
2. For Possible Action: Requests for further evaluation or proposed clinical criteria to be presented at a later date.

b. Opioid overdose deaths.

1. Discussion by the Board and review of utilization data.
2. For Possible Action: Requests for further evaluation or proposed clinical criteria to be presented at a later date.

c. Opioid Utilization – Top prescriber and member, including more than four concurrent opioids.

1. Discussion by the Board and review of utilization data.
2. For Possible Action: Requests for further evaluation or proposed clinical criteria to be presented at a later date.

d. Asthma and short-acting rescue inhaler utilization.

1. Discussion by the Board and review of utilization data.
2. For Possible Action: Requests for further evaluation or proposed clinical criteria to be presented at a later date.

7. Public comment on any Standard DUR report

8. Standard DUR reports

a. Review of Prescribing/Program Trends.

1. Top 10 Therapeutic Classes for Q3 2017, Q4 2017 and Q1 2018 (by payment and by claims).
2. Top 50 Drugs of Q3 2017, Q4 2017 and Q1 2018 (by payment and by claims).

b. Concurrent Drug Utilization Review (ProDUR).

1. Review of Q1 2018.
2. Review of top encounters by problem type.

c. Retrospective Drug Utilization Review (RetroDUR).

1. Status of previous quarter.
2. Status of current quarter.
3. Review and discussion of responses.

9. Closing discussion

a. Public comments on any subject.

b. Date and location of the next meeting.

1. Discussion of the time of the next meeting.

c. Adjournment.

PLEASE NOTE: Items may be taken out of order at the discretion of the chairperson. Items may be combined for consideration by the public body. Items may be pulled or removed from the agenda at any time. If an action item is not completed within the time frame that has been allotted, that action item will be continued at a future time designated and announced at this meeting by the chairperson. All public comment may be limited to five minutes.

Notice of this public workshop meeting and draft copies of the changes will be available on or after the date of this notice at the DHCFP Web site at http://dhcfp.nv.gov. The agenda posting of this meeting can be viewed at the follow locations: Carson City Central Office; Las Vegas District Office; Reno District Office; Elko District Office; Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Esmeralda County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Humboldt County Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.

If requested in writing, a copy of the meeting materials will be mailed to you. Requests and/or written comments may be sent to Colleen McLachlan at the Division of Health Care Financing

and Policy, 1100 E. William Street, Suite 101, Carson City, Nevada 89701, at least three days before the public hearing.

All persons that have requested in writing to receive the Public Hearings agenda have been duly notified by mail or e-mail.

Note: We are pleased to make accommodations for members of the public who have disabilities and wish to attend the meeting. If special arrangements are necessary, notify the Division of Health Care Financing and Policy as soon as possible and at least ten days in advance of the meeting, by e-mail at cmclachlan@dhcfp.nv.gov in writing, at 1100 East William Street, Suite 101, Carson City, Nevada 89701 or call Colleen McLachlan at (775) 684-3722.